Jan 8, 2018

Diabetes Drug Significantly Reverses Alzheimer's Like Memory Loss

A drug developed for diabetes could be used to treat Alzheimer’s after scientists found it significantly reversed memory loss.

A drug developed for diabetes could be used to treat Alzheimer’s after scientists found it “significantly reversed memory loss”
By Alzheimer's Reading Room

The findings are significant because the drug works by protecting the brain cells attacked by Alzheimer's disease in three separate ways; rather than, by relying on a single approach.

This is the first time that a triple receptor drug has been used which acts in multiple ways to protect the brain from degeneration.

A Diabetes Drug Has 'Significantly Reversed Memory Loss' in Mice With Alzheimer's

  • A drug developed for diabetes could be used to treat Alzheimer’s after scientists found it “significantly reversed memory loss” in mice through a triple method of action.

The research, published in Brain Research, could bring substantial improvements in the treatment of Alzheimer's disease through the use of a drug originally created to treat type 2 diabetes.

Lead researcher Professor Christian Holscher of Lancaster University in the UK said the novel treatment “holds clear promise of being developed into a new treatment for chronic neurodegenerative disorders such as Alzheimer’s disease.”

Dr Doug Brown, Director of Research and Development at Alzheimer’s Society, said:
“With no new treatments in nearly 15 years, we need to find new ways of tackling Alzheimer’s. It’s imperative that we explore whether drugs developed to treat other conditions can benefit people with Alzheimer’s and other forms of dementia. This approach to research could make it much quicker to get promising new drugs to the people who need them.

Although the benefits of these ‘triple agonist’ drugs have so far only been found in mice, other studies with existing diabetes drugs such as liraglutide have shown real promise for people with Alzheimer’s, so further development of this work is crucial.”

This is the first time that a triple receptor drug has been used which acts in multiple ways to protect the brain from degeneration.
  •  It combines GLP-1, GIP and Glucagon which are all growth factors. Problems with growth factor signalling have been shown to be impaired in the brains of Alzheimer’s patients.
The study used APP/PS1 mice, which are transgenic mice that express human mutated genes that cause Alzheimer’s. Those genes have been found in people who have a form of Alzheimer’s that can be inherited. Aged transgenic mice in the advanced stages of neurodegeneration were treated.

In a maze test, learning and memory formation were much improved by the drug which 
  1. enhanced levels of a brain growth factor which protects nerve cell functioning
  2. reduced the amount of amyloid plaques in the brain linked with Alzheimer’s
  3. reduced both chronic inflammation and oxidative stress
  4. slowed down the rate of nerve cell loss

Professor Holscher said:
“These very promising outcomes demonstrate the efficacy of these novel multiple receptor drugs that originally were developed to treat type 2 diabetes but have shown consistent neuro- protective effects in several studies.”
“Clinical studies with an older version of this drug type already showed very promising results in people with Alzheimer’s disease or with mood disorders”
Here we show that a novel triple receptor drug shows promise as a potential treatment for Alzheimer’s but further dose-response tests and direct comparisons with other drugs have to be conducted in order to evaluate if this new drugs is superior to previous ones.”
  • Type 2 diabetes is a risk factor for Alzheimer’s and has been implicated in the progression of the disease. 
  • Impaired insulin has been linked to cerebral degenerative processes in type 2 diabetes and Alzheimer's disease. 
  • Insulin desensitisation has also been observed in the Alzheimer's disease brain
  • The desensitisation could play a role in the development of neurodegenerative disorders as insulin is a growth factor with neuroprotective properties.

Alzheimer's and Diabetes from the Alzheimer's Reading Room

40 Percent of All Alzheimer's Cases Linked to Diabetes (Hyperinsulinemia)

Alcohol Consumption, Smoking, Obesity and Diabetes Associated with Alzheimer's Dementia

Related Articles from the Alzheimer's Reading Room

Mom Didn't Laugh for Two Years and Then I Had Her Thyroid Checked

The Connection Between UTI and Worsening Dementia

Alzheimer's Education

Learn More - Should You Agree with Dementia Patients

Learn More - How to Listen to a Person with Alzheimer's

Learn More - Coping with Dementia


How to Change Patterns of Behavior in Alzheimer's and Dementia Patients

Alzheimer's Patients Can Deceive Others to the Distress of Their Caregiver

The Alzheimer's Reading Room contains more than 5,000 articles and has been published daily since July, 2009.

You are reading original content the Alzheimer's Reading Room

Search the Alzheimer's Reading Room Award Winning Knowledge Base for Answers to Your Questions, and Solutions to Problems You FAce Each Day

We help Alzheimer’s patients to live a better live. We accomplish this by providing excellent advice and practical solutions to problems. Our solutions work and have been tested over time by millions of caregivers.

The Alzheimer's Reading Room is the number one source of high quality expert information for Alzheimer's care, dementia care, memory care, and for caregivers and dementia professionals.

The goal of the Alzheimer's Reading Room is to Educate and Empower Alzheimer's caregivers, their families, and the entire Alzheimer's and dementia community worldwide.

The Alzheimer's Reading Room operates for the benefit of society.

Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease
Brain Research, Volume 1678, Pages 64-74
Jingjing Tai, Weizhen Liu, Yanwei Li, Lin Li, Christian Hölscher